TABLE 1.
Baseline characteristics (full analysis set)
| Characteristic | IDegLira (n = 361) | Degludec (n = 179) | Liraglutide (n = 180) | Total (N = 720) |
|---|---|---|---|---|
| Age, y | 54.5 (10.3) | 55.7 (10.2) | 54.1 (10.2) | 54.7 (10.3) |
| Sex, n (%) | ||||
| Female | 142 (39.3) | 79 (44.1) | 72 (40.0) | 293 (40.7) |
| Male | 219 (60.7) | 100 (55.9) | 108 (60.0) | 427 (59.3) |
| Weight, kg | 74.8 (14.3) | 73.2 (13.2) | 73.8 (13.3) | 74.1 (13.8) |
| BMI, kg/m2 | 27.0 (3.9) | 26.5 (3.6) | 26.5 (3.6) | 26.7 (3.7) |
| Duration of diabetes, y | 8.00 (5.33) | 8.63 (5.55) | 8.05 (5.28) | 8.17 (5.37) |
| HbA1c, % | 8.20 (0.83) | 8.31 (0.84) | 8.21 (0.77) | 8.23 (0.82) |
| HbA1c, mmol/mol | 66.17 (9.06) | 67.34 (9.17) | 66.27 (8.44) | 66.48 (8.94) |
| Fasting plasma glucose, mmol/L | 9.61 (2.03) | 9.83 (2.07) | 9.55 (2.01) | 9.65 (2.04) |
| Fasting plasma glucose, mg/dL | 173.09 (36.67) | 177.13 (37.35) | 172.07 (36.28) | 173.84 (36.74) |
| OAD at screening, n (%) | ||||
| Metformin only | 118 (32.7) | 57 (31.8) | 59 (32.8) | 234 (32.5) |
| Metformin + sulfonylureas | 137 (38.0) | 71 (39.7) | 66 (36.7) | 274 (38.1) |
| Metformin + α‐glucosidase inhibitors | 74 (20.5) | 34 (19.0) | 37 (20.6) | 145 (20.1) |
| Metformin + glinides | 20 (5.5) | 13 (7.3) | 12 (6.7) | 45 (6.3) |
| Metformin + thiazolidinediones | 12 (3.3) | 4 (2.2) | 6 (3.3) | 22 (3.1) |
Note: Data are mean (SD) unless otherwise stated. Baseline refers to week 0, except for BMI, which was taken at screening (week −2). The duration of diabetes was calculated as the time from date of diagnosis to the randomization date.
Abbreviations: BMI, body mass index; degludec, insulin degludec; HbA1c, glycated hemoglobin; IDegLira, insulin degludec/liraglutide; OAD, oral antidiabetic drug; SD, standard deviation.